Special Emergency Project to Address COVID-19 with Novel Therapeutic Technology.
The NUCISION initiative is based on previous scientific research that originated with researchers from New Jersey, USA that was led by Dr. Stanley Stein.
His inventions include numerous patents spanning various scientific disciplines. He is noted for his involvement in the discovery and product development of Interferon also marketed as INTRON-A and Roferon-A, both FDA-Approved recombinant proteins used as an antiviral and anti-cancer treatment, at both Hoffman La Roche and Schering-Plough. Interferon is marketed in 82 countries for 16 major indications by Hoffman La Roche.
The technology being developed involves a unique approach that directly targets and destroys the COVID-19 Virus without the use of general antiviral approaches that include vaccines, antibodies, or interferon-based. Our patents and results of our preclinical and clinical research will be shared and will soon be made public. This formulation and mode of action is unique and will serve as a highly flexible therapeutic model that anticipates successful intervention at nearly all stages of the disease and can quickly address mutations without a lengthy discovery process.
NuCISION was formed in March of 2020. Its purpose is to rapidly develop and commercialize therapeutic solutions based on a novel and proprietary nanomolecular framework that can rapidly be tested and deployed.
Our founders and team are veterans in the biotechnology industry with a proven track record of drug development, FDA approvals, and commercialization experience.
The coronavirus pandemic spurred the creation of the company. However, being creators of a drug platform, we intend to leverage and expand our technology to address other devastating diseases, with a focus on viruses with pandemic potential.
As a platform product company we look forward to not just addressing the current pandemic, but to pioneering an adaptive and quick-response strategy based on a completely new and effective approach for cellular entry with viral targeting and degradation to achieve the destruction of RNA viruses within the cell.
Our tripartite and quadripartite therapeutic complexes attach viral molecules to destroy their ability to replicate. Currently, our goal for our therapeutic is an agile, effective, and quick model for topical administration in the airways for those infected with SARS-CoV-2.
This therapeutic has high biocompatibility and therefore has little potential for toxicity due to its composition. Our therapeutic is also highly scalable, as it is readily manufactured using established methods.
Our product is based on previous scientific research that originated with researchers from New Jersey, USA - a team that was led by Dr. Stanley Stein.
Dr. Stein's numerous breakthrough patented inventions span various scientific disciplines. He is noted for his involvement in the discovery and product development of Interferon Alpha also marketed as INTRON-A and Roferon-A, both of which are FDA approved recombinant proteins used as antiviral and anti-cancer treatments. These products are manufactured by Hoffmann La Roche and Schering-Plough. Interferon Alpha is marketed in eighty-two (82) countries for sixteen (16) major indications by Hoffman La Roche.
Our current platform involves a unique approach that goes beyond the scope of conventional antivirals. It uses targeting antisense technology coupled with complex components that allow efficient entry and subsequent destruction of SARS-CoV-2 RNA.
Our patents and the results of our preclinical and clinical research will be shared and will soon be made public. This formulation and mode of action is unique and will serve as a highly flexible therapeutic model that anticipates successful intervention at nearly all stages of the disease and can quickly address mutations without a lengthy discovery process.
We Are Creating A Therapeutic
Our global team with strong biopharma expertise works in unison and is paving the path to a better world.
While our team is working to bring you a solution, please feel free to browse the rest of the website to learn more about us.